FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda

It doesn’t happen that often, but Merck’s checkpoint inhibitor Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration (FDA). Six all at once, as a matter of fact.